D
Terns Pharmaceuticals, Inc. TERN
$2.92 -$0.13-4.26% NASDAQ
Recommendation
Prev Close
$2.92
Volume
806,225
Avg Vol (90D)
1,475,766
Market Cap
$254.91M
Dividend & Yield
--
52-Week Range
$1.87 - $11.40
P/E (TTM)
--
EPS (TTM)
-$1.13
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Geode Capital Management LLC Has $8.40 Million Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
4/26/2025 - MarketBeat
Townsquare Capital LLC Purchases Shares of 13,809 Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
4/24/2025 - Ticker Report
Terns Pharmaceuticals (NASDAQ:TERN) Given Market Outperform Rating at JMP Securities
4/23/2025 - MarketBeat
Video: Monday Sector Leaders: Biotechnology, Drugs
4/21/2025 - Market News Video
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Bought by Altium Capital Management LLC
4/20/2025 - MarketBeat
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Stock Position Raised by LPL Financial LLC
4/20/2025 - MarketBeat
Alliancebernstein L.P. Has $2.01 Million Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
4/19/2025 - MarketBeat
Vanguard Group Inc. Has $21.44 Million Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
4/17/2025 - MarketBeat
ExodusPoint Capital Management LP Lowers Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
4/16/2025 - MarketBeat
Terns Pharmaceuticals management to meet with Oppenheimer
4/15/2025 - The Fly
Terns Pharmaceuticals management to meet with Oppenheimer
4/14/2025 - The Fly
Terns Pharmaceuticals management to meet with Oppenheimer
4/8/2025 - TipRanks Financial Blog
Terns Pharmaceuticals management to meet with Oppenheimer
4/8/2025 - The Fly
Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround
4/7/2025 - Zacks Investment Research
Surprising Analyst 12-Month Target For VTHR
4/7/2025 - ETF Channel
Polymer Capital Management HK LTD Boosts Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
4/7/2025 - Ticker Report
Down -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals (TERN)
4/3/2025 - Zacks Investment Research
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)
4/2/2025 - GuruFocus
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)
4/2/2025 - Globe Newswire
Insider Purchases Worth US$5.17m See Losses As Terns Pharmaceuticals Market Value Drops To US$255m
3/31/2025 - Simply Wall St
Terns Pharmaceuticals (TERN, $3.12) Aroon Indicator entered a Downtrend on March 27, 2025.
3/28/2025 - Tickeron - Stocks
EntryPoint Capital LLC Buys New Shares in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
3/27/2025 - Ticker Report
Terns Pharmaceuticals (TERN, $3.1) Aroon Indicator entered a Downtrend on March 26, 2025.
3/27/2025 - Tickeron - Stocks
All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy
3/26/2025 - Zacks Investment Research
Terns Pharmaceuticals (TERN, $3.32) entered Downtrend as Momentum indicator drops below 0 level on Mar 25, 2025
3/26/2025 - Tickeron - Stocks
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$101.55M
EBIT (TTM)
-$101.87M
Net Income (TTM)
-$88.85M
Balance Sheet
Total Assets (Q)
$363.93M
Total Debt (Q)
$1.35M
Total Liabilities (Q)
$18.06M
Book Value Per Share (Q)
$3.97
Cash Flow
Cash from Operations (TTM)
-$70.02M
Cash from Investing (TTM)
-$12.41M
Cash from Financing (TTM)
$164.00M
Net Change in Cash (TTM)
$81.51M
Filings
Filing Date
Thursday, March 20, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
1.48
7-Day Total Return
30.36%
30-Day Total Return
-8.18%
60-Day Total Return
-37.07%
90-Day Total Return
-56.61%
Year to Date Total Return
-48.50%
1-Year Total Return
-40.53%
2-Year Total Return
-76.99%
3-Year Total Return
39.05%
5-Year Total Return
--
52-week Low
Apr 07, 2025 - $1.87
52-week High
Sep 10, 2024 - $11.40
Valuation
Market Cap
$254.91M - Micro Cap
Enterprise Value
-$101.91M
Price/Sales (TTM)
--
Price/Book (Q)
0.74
Dividends and Shares
Shares Outstanding
91.24M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.ternspharma.com
Phone Number
650 525 5535
Address
1065 East Hillsdale Boulevard
Foster City, CA 94404
Country
United States
Year Founded
2016
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an... more
NASDAQ 04/25/2025 4:00PM Eastern Quotes delayed